Abvc Biopharma (ABVC) Receivables (2012 - 2024)

Abvc Biopharma (ABVC) has reported Receivables for 9 consecutive years, with $1.2 million the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Receivables rose 92.66% year-over-year to $1.2 million; the trailing twelve-month figure through Sep 2024 stood at $1.2 million (up 92.66% YoY), and the FY2023 full-year result was $1.6 million, up 4.81% from the prior year.
• Receivables eased to $1.2 million in Q3 2024 per ABVC's latest filing, from $1.4 million in the prior quarter.
• Across five years, Receivables topped out at $1.5 million in Q4 2022 and bottomed at $47680.0 in Q3 2022.
• Historically, Receivables has averaged $704453.1 across 5 years, with a median of $625903.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables tumbled 89.92% in 2022, then surged 1212.72% in 2023.
• Over 5 years, Receivables stood at $303147.0 in 2020, then declined by 7.41% to $280692.0 in 2021, then soared by 439.63% to $1.5 million in 2022, then plunged by 44.37% to $842650.0 in 2023, then surged by 43.11% to $1.2 million in 2024.
• According to Business Quant data, Receivables over the past three periods registered $1.2 million, $1.4 million, and $889467.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.